VYNE Therapeutics (Nasdaq:VYNE) - Stock Price, News & Analysis

VYNE Stock Overview

A clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. More details

VYNE fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 70.65% per year

Risk Analysis

Earnings are forecast to decline by an average of 18.2% per year for the next 3 years

Makes less than USD$1m in revenue ($493K)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

+ 1 more risk

VYNE Therapeutics Inc. Competitors

ALT5 Sigma

NasdaqCM:ALTS

US$28.0m

Incannex Healthcare

NasdaqGM:IXHL

US$36.9m

Landos Biopharma

NasdaqCM:LABP

US$71.7m

Eyenovia

NasdaqCM:EYEN

US$8.0m

Price History & Performance

Summary of all time highs, changes and price drops for VYNE Therapeutics
Historical stock prices
Current Share Price	US$2.90
52 Week High	US$4.09
52 Week Low	US$1.57
Beta	1.35
11 Month Change	20.83%
3 Month Change	55.08%
1 Year Change	-25.64%
33 Year Change	-84.80%
5 Year Change	n/a
Change since IPO	-98.93%

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Oct 09

Recent updates

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

Aug 12

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

Jul 02

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Mar 19

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Jan 13

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Dec 03

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

Jun 30

Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Jun 07

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17

Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)

Feb 10

Shareholder Returns

	VYNE	US Pharmaceuticals	US Market
7D	2.1%	-3.8%	-1.0%
1Y	-25.6%	9.8%	30.3%

Return vs Industry: VYNE underperformed the US Pharmaceuticals industry which returned 9.8% over the past year.

Return vs Market: VYNE underperformed the US Market which returned 30.3% over the past year.

Price Volatility

Is VYNE's price volatile compared to industry and market?
VYNE volatility
VYNE Average Weekly Movement	9.8%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: VYNE has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: VYNE's weekly volatility (10%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2003	10	Dave Domzalski	www.vynetherapeutics.com

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company’s lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications.

VYNE Therapeutics Inc. Fundamentals Summary

How do VYNE Therapeutics's earnings and revenue compare to its market cap?
VYNE fundamental statistics
Market cap	US$41.60m
Earnings (TTM)	-US$34.09m
Revenue (TTM)	US$493.00k

86.8x

P/S Ratio

-1.3x

P/E Ratio

Is VYNE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VYNE income statement (TTM)
Revenue	US$493.00k
Cost of Revenue	US$0
Gross Profit	US$493.00k
Other Expenses	US$34.59m
Earnings	-US$34.09m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.31
Gross Margin	100.00%
Net Profit Margin	-6,915.62%
Debt/Equity Ratio	0%

How did VYNE perform over the long term?

See historical performance and comparison

VYNE Stock Overview

Rewards

Risk Analysis

VYNE Therapeutics Inc. Competitors

NasdaqCM:ALTS

US$28.0m

NasdaqGM:IXHL

US$36.9m

NasdaqCM:LABP

US$71.7m

NasdaqCM:EYEN

US$8.0m

Price History & Performance

Recent News & Updates

Consensus EPS estimates fall by 13%

VYNE Therapeutics Inc., Annual General Meeting, Dec 12, 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

VYNE Therapeutics Announces Positive Phase 1A Sad Data for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Recent updates

Consensus EPS estimates fall by 13%

VYNE Therapeutics Inc., Annual General Meeting, Dec 12, 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

VYNE Therapeutics Announces Positive Phase 1A Sad Data for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Consensus revenue estimates increase by 50%, EPS downgraded

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202

VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

Consensus EPS estimates upgraded to US$0.81 loss

First quarter 2024 earnings released: US$0.15 loss per share (vs US$1.72 loss in 1Q 2023)

Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo

Consensus EPS estimates upgraded to US$4.82 loss, revenue downgraded

Lead Independent Director recently bought US$51k worth of stock

New major risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors

VYNE Therapeutics Inc., Annual General Meeting, Dec 13, 2023

New major risk - Share price stability

Price target increased by 21% to US$16.50

New major risk - Market cap size

Consensus revenue estimates increase by 60%, EPS downgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

First quarter 2023 earnings released: US$1.72 loss per share (vs US$2.83 loss in 1Q 2022)

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Full year 2022 earnings released

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. announced that it has received $0.3 million in funding

VYNE Therapeutics Inc. Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

Consensus revenue estimates increase by 106%

Price target decreased to US$3.50

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$4.00

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

VYNE Therapeutics Inc. Announces Results from Its Phase 2a Trial of FMX114 for the Treatment of Mild-To-Moderate Atopic Dermatitis

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

VYNE Therapeutics Inc. Completes Enrollment in Phase 2A Trial of FMX 114 for the Treatment of Mild-To-Moderate Atopic Dermatitis

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$5.80

High number of new and inexperienced directors

VYNE Therapeutics Inc. Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

VYNE Therapeutics Inc. Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an in Vivo Model of Rheumatoid Arthritis

Consensus forecasts updated

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Reports Positive Preclinical Data for Lead Bet Inhibitor, VYN201, in Human Skin Model of Vitiligo